Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.49 |
| ▸ | PPARG | P37231 | 7/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4817990 | 1.00 | PPARA (0.49) | PPARAPPARGSMN1; SMN2SLC6A4FPR2 | |
| SCHEMBL10516010 | 0.91 | SMN1; SMN2 (0.46) | PPARAPPARGSMN1; SMN2SLC6A4FPR2 | |
| SCHEMBL21057182 | 0.89 | PPARG (0.48) | PPARAPPARGSMN1; SMN2SLC6A4FPR2 | |
| SCHEMBL21057180 | 0.89 | PPARG (0.48) | PPARAPPARGSMN1; SMN2SLC6A4FPR2 | |
| SCHEMBL21057108 | 0.87 | PPARA (0.50) | PPARAPPARGSLC6A4FPR2AAK1 | |
| SCHEMBL21057105 | 0.87 | PPARA (0.50) | PPARAPPARGSLC6A4FPR2AAK1 | |
| SCHEMBL21057154 | 0.85 | PPARA (0.49) | PPARAPPARGSLC6A4FPR2AAK1 | |
| SCHEMBL21057151 | 0.85 | PPARA (0.49) | PPARAPPARGSLC6A4FPR2AAK1 | |
| SCHEMBL8935782 | 0.85 | PPARA (0.52) | PPARAPPARGSMN1; SMN2MAPTPTGDR2 | |
| SCHEMBL8935780 | 0.85 | PPARA (0.52) | PPARAPPARGSMN1; SMN2MAPTPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731200-A1 | CLC-1 INHIBITORS FOR USE IN THE TREATMENT OF MULTIPLE SCLEROSIS AND NEUROMUSCULAR DISEASES | NMD Pharma A/S (DK) | 2026-04-29 | — | — | EP | claimed |
| WO-2024261020-A1 | CLC-1 INHIBITORS FOR USE IN THE TREATMENT OF MULTIPLE SCLEROSIS AND NEUROMUSCULAR DISEASES | NMD PHARMA A/S (DK) | 2024-12-26 | — | — | WO | claimed |
| EP-3723745-A1 | PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD Pharma A/S (DK) | 2020-10-21 | — | — | EP | claimed |
| CN-111587109-A | Phenoxy acids for the treatment of neuromuscular disorders | NMD制药股份公司 | 2020-08-25 | — | — | CN | claimed |
| WO-2019115777-A1 | PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | WO | claimed |
| US-20190183833-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA APS | 2019-06-20 | — | — | US | claimed |
| US-20190183834-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | claimed |
| EP-4731200-A1 | CLC-1 INHIBITORS FOR USE IN THE TREATMENT OF MULTIPLE SCLEROSIS AND NEUROMUSCULAR DISEASES | NMD Pharma A/S (DK) | 2026-04-29 | — | — | EP | disclosed |
| WO-2024261020-A1 | CLC-1 INHIBITORS FOR USE IN THE TREATMENT OF MULTIPLE SCLEROSIS AND NEUROMUSCULAR DISEASES | NMD PHARMA A/S (DK) | 2024-12-26 | — | — | WO | disclosed |
| EP-3723745-B1 | PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA AS (DK) | 2024-06-19 | — | — | EP | disclosed |
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-08-22 | — | — | US | disclosed |
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-08-22 | — | — | US | disclosed |
| US-11147788-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2021-10-19 | — | — | US | disclosed |
| EP-3723745-A1 | PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD Pharma A/S (DK) | 2020-10-21 | — | — | EP | disclosed |
| CN-111587109-A | Phenoxy acids for the treatment of neuromuscular disorders | NMD制药股份公司 | 2020-08-25 | — | — | CN | disclosed |
| WO-2019115777-A1 | PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | WO | disclosed |
| US-20190183833-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA APS | 2019-06-20 | — | — | US | disclosed |
| US-20190183834-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | PPARA 3247/4885PPARG 3332/4885SMN1; SMN2 13/4885 |
| US-20190183834-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | PPARA 3247/4885PPARG 3332/4885SMN1; SMN2 13/4885 |
| US-11147788-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | PPARA 3247/4885PPARG 3332/4885SMN1; SMN2 13/4885 |
| US-20190183833-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | PPARA 3247/4885PPARG 3332/4885SMN1; SMN2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.